Ipratropium Adultes Zentiva

Ipratropium Bromide, the active ingredient in Ipratropium Adultes Zentiva, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It treats chronic obstructive pulmonary disease (COPD), asthma and bronchospasm in adults.

GNH USA supplies Ipratropium Adultes Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium Bromide is a bronchodilator that acts on the muscarinic receptors of the airway smooth muscle, helping to manage obstructive lung diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces bronchoconstriction. - Asthma: provides additional bronchodilation when used with other controller therapies. - Bronchospasm: rapidly relieves acute narrowing of the airways.

Ipratropium Bromide may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Cough - Dry mouth - Throat irritation - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Paradoxical bronchospasm - Allergic reactions such as rash or angioedema - Severe cough or chest tightness - Respiratory distress - Acute worsening of asthma symptoms

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

- Assess respiratory status: ensure baseline lung function is documented. - Monitor for paradoxical bronchospasm: discontinue if severe narrowing occurs. - Use with caution in patients with narrow‑angle glaucoma: anticholinergic effects may increase intra‑ocular pressure. - Avoid in patients with urinary retention: may exacerbate bladder outflow obstruction. - Do not combine with other anticholinergic inhalers without medical supervision. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ipratropium Bromide can interact with other medications that affect the cholinergic system or bronchodilation.

Major Interactions (Avoid): - Concurrent use with other anticholinergic agents (e.g., tiotropium) – may increase anticholinergic load and risk of systemic effects. - Combination with high‑dose beta‑agonists – may lead to excessive cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Use with certain antihistamines that have anticholinergic properties – monitor for dry mouth and urinary retention. - Co‑administration with inhaled corticosteroids – generally safe but observe for any increase in local irritation. - Interaction with drugs that prolong QT interval – monitor cardiac rhythm if patient is at risk.